PMID- 27752910
OWN - NLM
STAT- MEDLINE
DCOM- 20170330
LR  - 20220317
IS  - 1993-1352 (Electronic)
IS  - 1672-0733 (Linking)
VI  - 36
IP  - 5
DP  - 2016 Oct
TI  - HLA-A*02-B*46 haplotype: an adverse prognostic factor in Han patients with 
      nasopharyngeal carcinoma.
PG  - 700-704
LID - 10.1007/s11596-016-1647-y [doi]
AB  - Epidemiological studies have shown that human leukocyte antigen (HLA) allelic 
      polymorphisms are closely correlated to susceptibility to nasopharyngeal 
      carcinoma (NPC), and in a previous study, we showed that HLA-B*46 and 
      HLA-A*02-B*46 haplotypes were strongly associated with NPC susceptibility. In 
      this retrospective study, we investigated the phenotype of the HLA-A and HLA-B 
      alleles and haplotypes and correlated these data to the clinical and pathological 
      parameters of NPC to understand the role of HLA alleles and haplotypes in NPC 
      prognosis. The cohort comprised 117 NPC patients from a Han population in 
      Xinjiang. The local recurrence-free survival (LRFS), distant metastasis- free 
      survival (DMFS), disease-free survival (DFS), and overall survival (OS) were 
      analyzed. The 5-year DMFS of the HLA-A*02-B*46 haplotype carriers and 
      non-carriers was 66.4% and 90.3%, respectively. In addition, age was found to be 
      a prognostic factor for LRFS, DFS, and OS (P=0.032, 0.040, and 0.013, 
      respectively). We found that the HLA-A*02-B*46 haplotype might be a prognostic 
      marker in addition to the traditional TNM staging in patients with NPC.
FAU - Wang, Ruo-Zheng
AU  - Wang RZ
AD  - Department of Head and Neck Radiation Oncology, the Affiliated Tumor Hospital of 
      Xinjiang Medical University, Urumqi, 830011, China.
FAU - Zhang, Dian-Gang
AU  - Zhang DG
AD  - Department of Head and Neck Radiation Oncology, the Affiliated Tumor Hospital of 
      Xinjiang Medical University, Urumqi, 830011, China.
FAU - Wu, Ran
AU  - Wu R
AD  - Department of Head and Neck Radiation Oncology, the Affiliated Tumor Hospital of 
      Xinjiang Medical University, Urumqi, 830011, China.
AD  - Department of Oncology, Bazhou People's Hospital of Mongolian Autonomous 
      Prefecture, Kuerle, 841000, China.
FAU - Hu, Yun-Hui
AU  - Hu YH
AD  - Department of Head and Neck Radiation Oncology, the Affiliated Tumor Hospital of 
      Xinjiang Medical University, Urumqi, 830011, China.
FAU - Peng, Yan-Chun
AU  - Peng YC
AD  - MRC Human Immunology Unit, Radcliffe Department of Medicine, Oxford University, 
      Oxford, OX3 9DS, UK.
FAU - Chang, Cheng
AU  - Chang C
AD  - Department of Head and Neck Radiation Oncology, the Affiliated Tumor Hospital of 
      Xinjiang Medical University, Urumqi, 830011, China.
FAU - Dong, Tao
AU  - Dong T
AD  - Department of Head and Neck Radiation Oncology, the Affiliated Tumor Hospital of 
      Xinjiang Medical University, Urumqi, 830011, China. tao.dong@imm.ox.ac.uk.
AD  - MRC Human Immunology Unit, Radcliffe Department of Medicine, Oxford University, 
      Oxford, OX3 9DS, UK. tao.dong@imm.ox.ac.uk.
AD  - Nuffield Department of Medicine, Oxford University, Oxford, OX3 9DU, UK. 
      tao.dong@imm.ox.ac.uk.
FAU - Wang, Xi-Yan
AU  - Wang XY
AD  - Department of Head and Neck Radiation Oncology, the Affiliated Tumor Hospital of 
      Xinjiang Medical University, Urumqi, 830011, China.
LA  - eng
GR  - G0600520/MRC_/Medical Research Council/United Kingdom
GR  - G1001046/MRC_/Medical Research Council/United Kingdom
GR  - MR/L018942/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
DEP - 20161018
PL  - China
TA  - J Huazhong Univ Sci Technolog Med Sci
JT  - Journal of Huazhong University of Science and Technology. Medical sciences = Hua 
      zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. 
      Yixue Yingdewen ban
JID - 101169627
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (HLA-A Antigens)
RN  - 0 (HLA-B Antigens)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*genetics
MH  - Carcinoma
MH  - Child
MH  - Disease-Free Survival
MH  - Female
MH  - HLA-A Antigens/*genetics
MH  - HLA-B Antigens/genetics
MH  - Haplotypes
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nasopharyngeal Carcinoma
MH  - Nasopharyngeal Neoplasms/*genetics/pathology
MH  - Neoplasm Metastasis
MH  - Neoplasm Staging
MH  - *Prognosis
MH  - Retrospective Studies
OTO - NOTNLM
OT  - human leukocyte antigens
OT  - metastasis
OT  - nasopharyngeal carcinoma
OT  - phenotype
OT  - prognosis
EDAT- 2016/10/19 06:00
MHDA- 2017/03/31 06:00
CRDT- 2016/10/19 06:00
PHST- 2016/05/18 00:00 [received]
PHST- 2016/08/21 00:00 [revised]
PHST- 2016/10/19 06:00 [pubmed]
PHST- 2017/03/31 06:00 [medline]
PHST- 2016/10/19 06:00 [entrez]
AID - 10.1007/s11596-016-1647-y [pii]
AID - 10.1007/s11596-016-1647-y [doi]
PST - ppublish
SO  - J Huazhong Univ Sci Technolog Med Sci. 2016 Oct;36(5):700-704. doi: 
      10.1007/s11596-016-1647-y. Epub 2016 Oct 18.